600668.SHG Zhejiang Jianfeng Group Co Ltd
- Market cap
- CNY 2.76B
- P/E
- -
- P/B
- 0.50x
- ROE
- -1.4%
- Dividend yield
- 2.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600668.SHG undervalued?
Graham numberThe Graham number of Zhejiang Jianfeng Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Jianfeng Group Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Jianfeng Group Co Ltd yet.
Zhejiang Jianfeng Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Jianfeng Group Co Ltd
Zhejiang Jianfeng Group Co., Ltd. engages in the building materials and pharmaceuticals business in China. The company offers pharmaceutical products, including antibiotics, cardiovascular drugs, antidepressants, ophthalmic drugs, anti-tumor drugs, and infant medications. It is involved in investment in pharmaceutical and healthcare industries; manufacturing and sales of cement and cement concrete; production and sales of pharmaceutical intermediates; sales of pharmaceutical…
Full company profileZhejiang Jianfeng Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Jianfeng Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.38B | 2.83B | 3.36B | 3.55B | 3.25B | 3.81B | 3.56B | 2.89B | 2.88B | 2.57B | 2.34B |
| Gross Profit | 578M | 958M | 1.40B | 1.44B | 1.20B | 1.23B | 954M | 638M | 676M | 572M | 356M |
| Operating Income | 352M | 504M | 838M | 964M | 750M | 1.22B | 434M | 130M | 209M | 46.8M | -42.3M |
| EBITDA | 514M | 646M | 993M | 1.11B | 918M | 1.41B | 653M | 373M | 485M | 760M | -26.6M |
| Net Income | 285M | 348M | 589M | 725M | 584M | 924M | 288M | 93.8M | 108M | 412M | -74.1M |
| EPS | 0.69 | 0.84 | 1.43 | 1.76 | 1.42 | 2.24 | 0.70 | 0.23 | 0.26 | 1.00 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 3.99B | 4.18B | 4.90B | 5.48B | 6.34B | 7.02B | 7.32B | 7.05B | 7.56B | 7.79B | 7.84B |
| Total Liabilities | 1.44B | 1.35B | 1.45B | 1.39B | 1.62B | 1.51B | 1.74B | 1.58B | 2.03B | 1.94B | 2.20B |
| Shareholders' Equity | 2.39B | 2.63B | 3.16B | 3.79B | 4.44B | 5.21B | 5.19B | 5.11B | 5.19B | 5.51B | 5.36B |
| Cash & Short-term Investments | 183M | 236M | 528M | 485M | 230M | 297M | 373M | 211M | 264M | 143M | 155M |
| Total Debt | 783M | 618M | 529M | 356M | 491M | 113M | 493M | 518M | 213M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 398M | 432M | 653M | 520M | 614M | 475M | 383M | 42.4M | 412M | 224M | - |
| Capital Expenditure | 66.6M | 114M | 115M | 347M | 559M | 304M | 456M | 237M | 339M | 675M | 488M |
| Free Cash Flow | 332M | 318M | 538M | 173M | 55.3M | 171M | -73.0M | -195M | 73.3M | -451M | -375M |
| Ratios | |||||||||||
| ROE | 12.0% | 13.3% | 18.6% | 19.1% | 13.2% | 17.7% | 5.5% | 1.8% | 2.1% | 7.5% | -1.4% |
| ROA | 7.1% | 8.3% | 12.0% | 13.2% | 9.2% | 13.2% | 3.9% | 1.3% | 1.4% | 5.3% | -0.9% |
| Net Profit Margin | 12.0% | 12.3% | 17.5% | 20.4% | 18.0% | 24.3% | 8.1% | 3.2% | 3.8% | 16.0% | -3.2% |
| Debt to Equity | 0.33x | 0.24x | 0.17x | 0.09x | 0.11x | 0.02x | 0.10x | 0.10x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Jianfeng Group Co Ltd dividends
- Dividend yield
- 2.02%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 13.5%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 55.6M | 0.13 | 13.5% |
| 2024 | CNY 53.8M | 0.13 | 49.8% |
| 2023 | CNY 67.1M | 0.16 | 71.6% |
| 2022 | CNY 172M | 0.42 | 59.8% |
| 2021 | CNY 150M | 0.36 | 16.2% |
| 2020 | CNY 103M | 0.25 | 17.7% |
| 2019 | CNY 127M | 0.31 | 17.5% |
| 2018 | CNY 71.8M | 0.17 | 12.2% |
| 2017 | CNY 123M | 0.30 | 35.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jul 15, 2025.
Who owns Zhejiang Jianfeng Group Co Ltd
- Insiders 25.03%
- Institutions 3.11%
- Public & others 71.86%
- Shares outstanding 413M
- Free float 275M
Zhejiang Jianfeng Group Co Ltd company profile
- Company name
- Zhejiang Jianfeng Group Co Ltd
- Ticker
- 600668.SHG
- ISIN
- CNE000000B18
- Exchange
- Shanghai Stock Exchange
- Listed since
- Dec 1, 1992
- Sector
- Basic Materials
- Industry
- Industrial Conglomerates
- Employees
- 1,836
- Fiscal year end
- December
- Address
- No. 88, Wujiang East Road, Jinhua, China, 321000
- Phone
- 86 57 9823 20582
- Website
- jianfeng.com.cn
About Zhejiang Jianfeng Group Co Ltd
Zhejiang Jianfeng Group Co., Ltd. engages in the building materials and pharmaceuticals business in China. The company offers pharmaceutical products, including antibiotics, cardiovascular drugs, antidepressants, ophthalmic drugs, anti-tumor drugs, and infant medications. It is involved in investment in pharmaceutical and healthcare industries; manufacturing and sales of cement and cement concrete; production and sales of pharmaceutical intermediates; sales of pharmaceutical chemical raw materials; and import and export business; and other industrial investments. Zhejiang Jianfeng Group Co., Ltd. was incorporated in 1989 and is based in Jinhua, China.
Zhejiang Jianfeng Group Co Ltd management
6- Mr. Jian Hong YuGM & Director · born 1966
- Mr. Xiao Long LanChief Financial Officer · born 1973
- Mr. Feng Liang ZhangExecutive Deputy GM & Employee Representative Director · born 1977
- Mr. Jianwei ZhuSecretary of the Board · born 1967
- Mr. Hongwei HuDeputy General Manager · born 1972
- Defu WuAccounting Supervisor